Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients: Insights from the Statistical Analysis of Survey Data

2024

Combination Therapy for Infections in Pediatric Cancer Patients

Sample size: 685 publication 10 minutes Evidence: moderate

Author Information

Author(s): Elio Castagnola, Francesca Bagnasco, Alessio Mesini, Philipp K. A. Agyeman, Roland A. Ammann, Marta Arrabito, Fabianne Carlesse, Maria Rosaria D'Amico, Giovanna Giagnuolo, Gabrielle M. Haeusler, Evgeny A. Idelevich, Christa Koenig, Thomas Lehrnbecher, Marie Luckowitsch, Mariaclaudia Meli, Giuseppe Menna, Giovanna Russo, Maria Elena Santolaya de Pablo, Arne Simon, Galina Solopova, Lillian Sung, Annalisa Tondo, Andreas H. Groll

Primary Institution: IRCCS Istituto Giannina Gaslini

Hypothesis

Does the addition of a second antibiotic improve outcomes for pediatric cancer patients with Gram-negative bloodstream infections?

Conclusion

Combination therapy can reduce the incidence of treatment failure linked to antibacterial resistance among Gram-negative isolates in bloodstream infections.

Supporting Evidence

Combination therapies with amikacin had a lower percentage of resistant isolates compared to monotherapy.
ICU admission was needed in 15.1% of cases and death occurred in 8.1%.
Resistance to both drugs in combination therapy was significantly associated with higher mortality.
Neutropenia was present in 73.4% of the bloodstream infection episodes.

Takeaway

Using two antibiotics together can help sick kids with infections get better, especially when one medicine isn't working well on its own.

Methodology

Data was collected from a large multinational study on antibiotic susceptibility in Gram-negative bloodstream infections.

Potential Biases

Potential for incomplete data on antibiotic susceptibility and variations in local practices.

Limitations

The study is retrospective and based on local epidemiology, which may not reflect current resistance patterns.

Participant Demographics

Pediatric cancer patients with febrile neutropenia, primarily aged under 18.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/antibiotics13121160

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication

Home